Inmagene has established a strategic partnership with HUTCHMED (Nasdaq/AIM: HCM) to develop highly innovative drug candidates. Furthermore, Inmagene has out-licensed IMG-018, an in-house developed asset, to Aditum Bio. This collaboration has launched Celexor Bio, a new biotech leveraging IMG-018.
Inmagene offers a portfolio of differentiated assets that are currently available for partnership opportunities.